Published in Br Med J on February 23, 1980
A Different Approach to Preventing Thrombosis (ADAPT) | NCT02774265
Antiplatelet drugs: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest (2012) 1.31
Deep vein thrombosis: a clinical review. J Blood Med (2011) 1.15
Does aspirin have a role in venous thromboembolism prophylaxis in total knee arthroplasty patients? J Arthroplasty (2009) 1.07
Antiplatelet treatment for thromboprophylaxis: a step forward or backwards? BMJ (1994) 0.99
Venous thromboembolism in urologic surgery: prophylaxis, diagnosis, and treatment. Rev Urol (2010) 0.79
Prevention of venous thrombosis with minidose warfarin after joint replacement. BMJ (1991) 0.78
Venous thromboembolic prophylaxis for hip fractures. Osteoporos Int (2010) 0.78
Evidence-base for aspirin as venous thromboembolic prophylaxis following joint replacement. Bone Joint Res (2014) 0.76
Effect on deep venous thrombosis with flexion during total knee arthroplasty. HSS J (2006) 0.75
Physical methods of prophylaxis against venous thrombosis. Br Med J (Clin Res Ed) (1981) 0.75
Leg ulcers past and present. J R Coll Gen Pract (1981) 0.75
The principles and practice of anticoagulant therapy. Can Fam Physician (1987) 0.75
Aspirin prophylaxis of venous thromboembolism after total hip replacement. N Engl J Med (1977) 1.65
Thrombogenic effect of high-dose aspirin in rabbits. Relationship to inhibition of vessel wall synthesis of prostaglandin I2-like activity. J Clin Invest (1978) 1.43
Thromboembolism after total hip reconstruction. Failure of low doses of heparin in prevention. JAMA (1973) 1.39
THE ACCELERATION OF LINEAR FLOW IN THE DEEP VEINS OF THE LOWER EXTREMITY OF MAN BY LOCAL COMPRESSION. J Clin Invest (1949) 1.23
Thromboembolic disease in patients undergoing total knee replacement. J Bone Joint Surg Am (1976) 1.03
The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg (1975) 1.00
Editorial: Lwo=dose heparin prophylaxis for postoperative venous thromboembolism. N Engl J Med (1975) 0.98
Acetylsalicylic acid in a trial to diminish thromboembolic complications after elective hip surgery. Acta Orthop Scand (1975) 0.97
[Prevention of thromboembolism using acetylsalicylic acid in the surgery of hip-joint proximal fractures]. Monatsschr Unfallheilkd Versicher Versorg Verkehrsmed (1974) 0.94
The effect of adenosine monophosphate, arcaine and anti-inflammatory agents on thrombosis and platelet function in rabbits. Thromb Diath Haemorrh (1970) 0.89
Antithrombotic practice in orthopedic surgery. Results of a survey. Clin Orthop Relat Res (1975) 0.87
[Fractures of the upper tibia and thromboembolic risk]. Agressologie (1976) 0.85
Tracheobronchial tree: expandable metallic stents used in experimental and clinical applications. Work in progress. Radiology (1986) 2.05
Structure determination of feline panleukopenia virus empty particles. Proteins (1993) 1.99
CD31/PECAM-1 is a ligand for alpha v beta 3 integrin involved in adhesion of leukocytes to endothelium. J Cell Biol (1995) 1.93
Structure of a viral procapsid with molecular scaffolding. Nature (1997) 1.85
Adjusted versus fixed-dose subcutaneous heparin in the prevention of deep-vein thrombosis after total hip replacement. N Engl J Med (1983) 1.85
Determination of the vasodilator UK33274 by high-performance liquid chromatography using fluorescence detection. J Chromatogr (1980) 1.79
Characterization of plasminogen activators from normal human breast and colon and from breast and colon carcinomas. Int J Cancer (1984) 1.72
New directions in information for patients. BMJ (1995) 1.67
Pathophysiology of endotoxin shock in the primate. Am J Obstet Gynecol (1970) 1.65
Prevention of deep vein thrombosis after hip replacement: randomised comparison between unfractionated heparin and low molecular weight heparin. BMJ (1991) 1.65
Aboriginals with multiple sclerosis: HLA types and predominance of neuromyelitis optica. Neurology (2001) 1.61
Quantitation of allograft fibrosis and chronic allograft nephropathy. Pediatr Transplant (1999) 1.60
Beneficial effects of treatment of early subclinical rejection: a randomized study. J Am Soc Nephrol (1998) 1.54
Sintered fiber metal composites as a basis for attachment of implants to bone. J Bone Joint Surg Am (1971) 1.48
Demonstration of a fast-acting inhibitor of plasminogen activators in human plasma. Blood (1984) 1.44
Investigation of early T cell activation: analysis of the effect of specific antigen, interleukin 2 and monoclonal antibodies on intracellular free calcium concentration. Eur J Immunol (1985) 1.41
Diffusing capacity limitations of the extent of lung volume reduction surgery in an animal model of emphysema. J Thorac Cardiovasc Surg (1999) 1.39
The structure of human parvovirus B19 at 8 A resolution. Virology (1994) 1.38
Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb (1993) 1.38
Deletions within the LMP1 oncogene of Epstein-Barr virus are clustered in Hodgkin's disease and identical to those observed in nasopharyngeal carcinoma. Blood (1993) 1.35
A deletion in the gene encoding the CD45 antigen in a patient with SCID. J Immunol (2001) 1.34
Purification and characterization of a plasminogen activator inhibitor from the histiocytic lymphoma cell line U-937. J Biol Chem (1986) 1.33
Vitamin A metabolism and requirements in the human studied with the use of labeled retinol. Vitam Horm (1974) 1.32
Fibrinolysis in pregnancy: a study of plasminogen activator inhibitors. Blood (1987) 1.29
A model for studies of mechanical interactions between the human spine and rib cage. J Biomech (1974) 1.24
Structural analysis of the Spiroplasma virus, SpV4: implications for evolutionary variation to obtain host diversity among the Microviridae. Structure (1998) 1.24
Tissue plasminogen activator: chemical and physiological aspects. Semin Thromb Hemost (1984) 1.23
p130/E2F4 binds to and represses the cdc2 promoter in response to p53. J Biol Chem (2000) 1.22
Signal transduction in human T lymphocytes. Immunol Rev (1987) 1.21
Structure of the Maize streak virus geminate particle. Virology (2001) 1.20
Necrosis of skin induced by coumarin in a patient deficient in protein S. BMJ (1989) 1.20
[Incidence of intramural digestive system hematoma in anticoagulation. Epidemiologic study and clinical aspects of 59 cases observed in Switzerland (1970-1975)]. Schweiz Med Wochenschr (1983) 1.19
Biochemical and physical characterization of parvovirus minute virus of mice virus-like particles. Virology (2000) 1.18
Coeliac disease and diabetes mellitus: a study of 24 patients with HLA typing. Q J Med (1982) 1.17
Different pathways of human T-cell activation revealed by PHA-P and PHA-M. Immunology (1986) 1.16
Association between histocompatability antigens (HLA) and nasal carriage of Staphylococcus aureus. J Med Microbiol (1983) 1.16
Audit and the quality of clinical care: patient satisfaction. Ann R Coll Surg Engl (1991) 1.15
Structural and kinetic analysis of the chemical rescue of the proton transfer function of carbonic anhydrase II. Biochemistry (2001) 1.14
Plasminogen activator inhibitor 1: a new prognostic marker in septic shock. Thromb Haemost (1989) 1.12
Plasminogen activator expression in human atherosclerotic lesions. Arterioscler Thromb Vasc Biol (1995) 1.11
Expression of p150 in cervical neoplasia and its potential value in predicting survival. Cancer (1998) 1.11
Informed consent in clinical trials. Should be comprehensive... BMJ (1993) 1.10
Green fluorescent protein as a novel tool to measure apoptosis and necrosis. Cytometry (2001) 1.10
Plasminogen activators, plasminogen activator inhibitors and procoagulant analyzed in twenty human tumor cell lines. Int J Cancer (1986) 1.10
Complications following total knee replacement. Clin Orthop Relat Res (1977) 1.09
Family and population studies of HLA and coeliac disease in the West of Ireland. Tissue Antigens (1983) 1.08
Clopidogrel loading dose regimens: kinetic profile of pharmacodynamic response in healthy subjects. Semin Thromb Hemost (1999) 1.08
A point mutation in CD45 may be associated with an increased risk of HIV-1 infection. AIDS (2001) 1.08
Isolation from human plasma of a plasminogen activator identical to urinary high molecular weight urokinase. J Clin Invest (1982) 1.04
Thromboembolic disease in patients undergoing total knee replacement. J Bone Joint Surg Am (1976) 1.03
Identification of aleutian mink disease parvovirus capsid sequences mediating antibody-dependent enhancement of infection, virus neutralization, and immune complex formation. J Virol (2001) 1.03
Age-related changes, including synergy and suppression, in the mixed lymphocyte reaction in long-lived mice. Fed Proc (1975) 1.02
Identification of clinical and histopathologic risk factors for diminished renal function 2 years posttransplant. J Am Soc Nephrol (1998) 1.01
The hemostatic mechanism after open-heart surgery. II. Frequency of abnormal platelet functions during and after extracorporeal circulation. J Thorac Cardiovasc Surg (1975) 1.00
Physical properties of trabecular bone. Calcif Tissue Res (1970) 1.00
Clinical pharmacokinetics of doxazosin in a controlled-release gastrointestinal therapeutic system (GITS) formulation. Br J Clin Pharmacol (1999) 0.99
A first-principles density-functional calculation of the electronic and vibrational structure of the key melanin monomers. J Chem Phys (2004) 0.98
Anthracene-9,10-diones as potential anticancer agents. Synthesis, DNA-binding, and biological studies on a series of 2,6-disubstituted derivatives. J Med Chem (1992) 0.98
The fast-acting inhibitor of tissue-type plasminogen activator in plasma is also the primary plasma inhibitor of urokinase. Thromb Haemost (1986) 0.98
Plasminogen activator inhibitor 1 and plasminogen activator inhibitor 2 in various disease states. Thromb Haemost (1988) 0.97
Pharmacokinetic study of gentamicin-loaded cement in total hip replacements. Comparative effects of varying dosage. J Bone Joint Surg Br (1984) 0.97
Preliminary investigation of the phage phi X174 crystal structure. J Mol Biol (1990) 0.96
Clinical rejection is distinguished from subclinical rejection by increased infiltration by a population of activated macrophages. J Am Soc Nephrol (1999) 0.96
Fibroblasts prevent apoptosis of IL-2-deprived T cells without inducing proliferation: a selective effect on Bcl-XL expression. Immunology (1996) 0.96
Preliminary joint neutron and X-ray crystallographic study of human carbonic anhydrase II. Acta Crystallogr Sect F Struct Biol Cryst Commun (2009) 0.96
Calcium ion-induced structural changes in bacteriophage phi X174. J Mol Biol (1994) 0.95
Studies on the release of a plasminogen activator inhibitor by human platelets. Thromb Haemost (1986) 0.95
Overexpression of p150, a part of the large subunit of the eukaryotic translation initiation factor 3, in colon cancer. Anticancer Res (2010) 0.95
Is warfarin sodium contraindicated in the lactating mother? J Pediatr (1983) 0.94
Molecular analysis of the LMP (latent membrane protein) oncogene in Hodgkin's disease. Leukemia (1993) 0.93
Phase I and pharmacokinetic study of D-verapamil and doxorubicin. Br J Cancer (1991) 0.93
Tissue-type plasminogen activator increases the binding of glu-plasminogen to clots. J Clin Invest (1984) 0.93
Mutational hot spots within the carboxy terminal region of the LMP1 oncogene of Epstein-Barr virus are frequent in lymphoproliferative disorders. Oncogene (1995) 0.93
Surgical resection of stage IIIA and stage IIIB non-small-cell lung cancer after concurrent induction chemoradiotherapy. A Southwest Oncology Group trial. J Thorac Cardiovasc Surg (1993) 0.93
Detection of Epstein-Barr virus DNA by polymerase chain reaction in lymph node biopsies from patients with angioimmunoblastic lymphadenopathy. Br J Haematol (1990) 0.92
Tissue transglutaminase enzyme-linked immunosorbent assay as a screening test for celiac disease in pediatric patients. Pediatrics (2001) 0.92
Superior mesenteric and portal vein thrombosis following laparoscopic-assisted right hemicolectomy. Report of a case. Dis Colon Rectum (1996) 0.92
Reversible, hepatic, lysosomal phospholipidosis in rat induced by subchronic daily administration of trospectomycin sulfate. Biochem Pharmacol (1989) 0.92
Plasminogen activators and plasminogen activator inhibitors in liver deficiencies caused by chronic alcoholism or infectious hepatitis. Thromb Haemost (1989) 0.91
Characterization of the in vitro phosphorylation of human tau by tau protein kinase II (cdk5/p20) using mass spectrometry. J Neurochem (2001) 0.91
The exon A (C77G) mutation is a common cause of abnormal CD45 splicing in humans. J Immunol (2001) 0.91
Functional subsets of T cells defined by isoforms of CD45. Biochem Soc Trans (1992) 0.90
Efficacy of systemic therapies for moderate-to-severe psoriasis: a systematic review and meta-analysis of long-term treatment. J Eur Acad Dermatol Venereol (2012) 0.90
Expression of LDL receptor-related protein/alpha 2-macroglobulin receptor in human normal and atherosclerotic arteries. Arterioscler Thromb (1994) 0.89
Low molecular weight heparin Novo (LHN-1) does not cross the placenta during the second trimester of pregnancy. Thromb Haemost (1989) 0.89
A DNA-porphyrin minor-groove complex at atomic resolution: the structural consequences of porphyrin ruffling. Proc Natl Acad Sci U S A (2000) 0.89
Peritubular capillary basement membrane reduplication in allografts and native kidney disease: a clinicopathologic study of 278 consecutive renal specimens. Transplantation (2001) 0.88
Histopathology of myelodysplastic syndromes. The FAB classification (proposals) applied to bone marrow biopsy. Am J Clin Pathol (1987) 0.88
Video-assisted thoracoscopic surgery in the management of penetrating and blunt thoracic trauma. J Minim Access Surg (2009) 0.88
Plasminogen activators in dextran sulfate-activated euglobulin fractions: a molecular analysis of factor XII- and prekallikrein-dependent fibrinolysis. Blood (1989) 0.88
A point mutation within CD45 exon A is the cause of variant CD45RA splicing in humans. Eur J Immunol (1998) 0.87
Hematopoietic studies in vitamin A deficiency. Am J Clin Nutr (1978) 0.87
Epstein-Barr virus burden in Hodgkin's disease is related to latent membrane protein gene expression but not to active viral replication. Blood (1992) 0.86
Age-related changes in the cellular immune response of lymph node and thymus cells in long-lived mice. Cell Immunol (1975) 0.85
Fixation of skeletal replacement by fiber metal composites. Clin Orthop Relat Res (1972) 0.85